September 6, 2024 07:15 AM EDT

GSK’s Nucala cuts exacerbations in Phase 3 COPD trial, but numbers remain under wraps

Ayisha Sharma

News Reporter

GSK’s Nucala passed a late-phase test in chronic obstructive pulmonary disorder, setting the stage for a showdown against a new group of contenders that is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GSK’s Nucala cuts exacerbations in Phase 3 COPD trial, but numbers remain under wraps

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Post-Hoc: Big promises built Moderna. They might also be its undoing

GSK’s Nu­cala cuts ex­ac­er­ba­tions in Phase 3 COPD tri­al, but num­bers re­main un­der wraps

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

GSK’s Nucala cuts exacerbations in Phase 3 COPD trial, but numbers remain under wraps